Abstract
Lenalidomide, a daughter molecule of Thalidomide, and IMIDs are immunomodulatory drugs that have been described as having immunomodulatory properties and anti-tumor activity. The effect of Lenalidomide towards Peripheral Blood Mononuclear Cells (PBMC) has been studied and direct effects towards T cells have been described, such as an increase of interferon-gamma (IFN-gamma) and interleukin (IL)-2 production. As a consequence, it has been also described that IL-2 subsequently activates Natural Killer (NK) cells. Nevertheless, direct effects of Lenalidomide on NK cells from healthy volunteers have never been described, if searched. Here we show that Lenalidomide can inhibit the production of IFN-gamma by NK cells from healthy donors. It also modifies the phenotype of NK cells through a decrease of the expression of Killer cell Immunoglobulin-like Receptors (KIRs) and NKp46. However, we did not detect consequence of these phenotype modifications on the cytotoxic potential of NK cells.
References
Mar 1, 1991·The Journal of Experimental Medicine·E P SampaioG Kaplan
Jun 10, 1998·The Journal of Experimental Medicine·P A HaslettG Kaplan
Jun 22, 2001·Blood·F E DaviesK C Anderson
Nov 8, 2001·Trends in Immunology·M A CooperM A Caligiuri
Oct 18, 2002·Blood·Paul G RichardsonKenneth C Anderson
Apr 2, 2004·Nature Reviews. Cancer·J Blake BartlettAngus G Dalgleish
Jan 11, 2005·British Journal of Haematology·Toshiaki HayashiKenneth C Anderson
Feb 11, 2005·The New England Journal of Medicine·Alan ListJerome B Zeldis
Feb 19, 2005·Drug Discovery Today·Steve K TeoJerome B Zeldis
Nov 1, 2006·Cancer·Toni K ChoueiriRonald M Bukowski
Nov 8, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Asher Chanan-KhanMyron S Czuczman
May 10, 2007·Leukemia & Lymphoma·Stefano Molica
Oct 2, 2007·Current Opinion in Oncology·Jose Ortega, Alan List
Apr 9, 2008·Cancer Immunology, Immunotherapy : CII·Dan ZhuBernd Stein
Aug 9, 2008·Journal of Leukocyte Biology·Mary PoupotRémy Poupot
Feb 25, 2009·Expert Opinion on Pharmacotherapy·Christine Galustian, Angus Dalgleish
Sep 26, 2009·Journal of Translational Medicine·Damien PortevinRemy Poupot
Citations
Mar 17, 2012·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Shancheng RenYinghao Sun
Jul 14, 2011·Investigational New Drugs·Martin Schmidt-HieberIgor Wolfgang Blau
Dec 8, 2015·Immunotherapy·Maria StamouliPanagiotis Tsirigotis
Jan 12, 2012·Journal of Chemotherapy·V Kumar, S Chhibber
Apr 10, 2014·Frontiers in Immunology·Anne-Sophie ChretienDaniel Olive
Nov 28, 2016·Experimental Hematology·Manh-Cuong VoJe-Jung Lee
Jan 16, 2013·Oncogene·J ShorttR W Johnstone
Feb 16, 2017·Oncotarget·Massimo GiulianiGuy Berchem
May 22, 2018·Frontiers in Immunology·Aude Le RoyDaniel Olive
Apr 2, 2020·Cancers·Kanako ShimizuAnd Shin-Ichiro Fujii
Oct 31, 2020·Dermatologic Therapy·Naveed PervaizRavinder Kumar
Sep 6, 2018·Current Medicinal Chemistry·Enrica BalzaLorenzo Mortara
Feb 2, 2021·Pigment Cell & Melanoma Research·Naveed PervaizRavinder Kumar
Jul 14, 2020·Dermatology : International Journal for Clinical and Investigative Dermatology·Sandra DomingoJosefina Cortés-Hernández